In the LMCI and AD groups, APOE-ε4 carriers showed significantly higher levels of volume reduction than non-carriers did, whereas no significant difference in volumetric changes was found between carriers and non-carriers in control subjects (Figure 3B). Here, APOE is linked to Alzheimer disease.